Stockreport

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 [Yahoo! Finance]

Molecular Partners AG - American Depositary Shares  (MOLN) 
PDF Positive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profile First-in-human study in planning with initial data expected in 202 [Read more]